This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Merck Serono S. a.. Active years: 2012-2014.
Company Filing History:
Years Active: 2012-2014
Title: Cedric Merlot: Innovator in CRTH2 Modulation
Introduction
Cedric Merlot is a notable inventor based in Collonges-sous-Salève, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target CRTH2 activity. With a total of 2 patents, his work focuses on addressing allergic diseases and inflammatory conditions.
Latest Patents
Merlot's latest patents include two innovative inventions. The first patent, titled "2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors," relates to the use of these compounds for the treatment and prevention of allergic diseases, inflammatory dermatoses, and other conditions with an inflammatory component. This invention emphasizes the modulation and inhibition of CRTH2 activity. The second patent, "Tricyclic spiro derivatives as CRTH2 modulators," also targets similar health issues by utilizing spiro derivatives for the modulation of CRTH2 activity.
Career Highlights
Cedric Merlot is currently associated with Merck Serono S.A., where he continues to advance his research in the pharmaceutical industry. His work has the potential to significantly impact the treatment of various inflammatory diseases.
Collaborations
Merlot collaborates with esteemed colleagues, including Patrick Naxos Page and Matthias Schwarz, to further enhance the development of innovative therapeutic solutions.
Conclusion
Cedric Merlot's contributions to the field of medicinal chemistry, particularly through his patents targeting CRTH2 modulation, highlight his role as an influential inventor. His ongoing work at Merck Serono S.A. promises to lead to advancements in the treatment of allergic and inflammatory diseases.